Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye

Postorino, Elisa Imelde; Rania, Laura; Aragona, Emanuela; Mannucci, Carmen; Alibrandi, Angela; Calapai, Gioacchino; Puzzolo, Domenico; Aragona, Pasquale

doi:10.5301/ejo.5001011

Cited by 34 publications

(36 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are few studies regarding cross-linked HA, especially in humans, 47,48 but these preliminary reports have confirmed that it could represent a new valid option for treatment of patients affected by mild-to-moderate dry eye.…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Cross-Linked Hyaluronic Acid as Tear Film Substitute

Posarelli

Passani

et al. 2019

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

The aim of this review is to clarify the role of cross-linked Hyaluronic acid (HA) molecule as a tear supplement and to define its possible applications in dry eye disease. Methods: Current Literature about HA and its cross-linked derivatives has been examined. Results: HA is superior in increasing the viscosity and stability of the tear film compared with other tear supplements such as polyvinyl alcohol, hydroxypropyl methylcellulose, carboximethyl cellulose and polyethylene glycol. Moreover, HA can be modified in different ways to improve its properties such as molecular weight, viscosity, and hydrophobicity to adapt the new artificial molecule to different aims. Conclusions: The current pharmacological trend is to improve the properties of HA by cross-linking parts of the molecule to achieve better bioavailability and resistence to degradation. In dry eye disease, cross-linked HA as tear supplement seems to provide better ocular comfort than linear HA and is therefore subjected to growing interest and diffusion.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

“…Recently, Postorino et al published their results about the use of cross-linked HA and coenzyme Q10 in treating patients with mild-to-moderate dry eye. 48 This was a randomized, single-masked, parallel group, and comparative study. Forty patients with mild-to-moderate dry eye disease were enrolled.…”

Section: Fig 2 Example Of a Crosslinked Ha Moleculementioning

confidence: 99%

Cross-Linked Hyaluronic Acid as Tear Film Substitute

Posarelli

Passani

et al. 2019

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…In the first study conducted in vitro, [15] corneal epithelialization improved with two artificial tear formulations containing crosslinked hyaluronic acid combined with 0.02% and 0.4% urea; both compounds quantitatively improved the ocular surface. A recently published study examined the efficacy of an artificial tear containing crosslinked hyaluronic acid combined with coenzyme Q10 [16] and concluded that the resulting effect on the ocular surface is greater than that with hyaluronic acid alone. The hyaluronic acid/coenzyme Q10 combination led to a reduction in the OSDI score and in corneal and conjunctival staining.…”

Section: Contact Lenses and Mgdmentioning

confidence: 99%

“…Crosslinked hyaluronic acid confers a higher molecular weight to the polysaccharide chain and has been investigated in recent studies, used alone and combined with other elements. [15,16] The purpose of this study was to evaluate the clinical efficacy of 0.4% uncrosslinked hyaluronic acid and 0.2% galactoxyloglucan (tear A) and 0.15% crosslinked (CXL) hyaluronic acid, crocin, and liposomes (tear B) in dry eye disease caused by meibomian gland dysfunction.…”

mentioning

confidence: 99%

Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction

Sánchez‐González

De-Hita-Cantalejo

Sánchez-González

2019

Preprint

View full text Add to dashboard Cite

Background: To study the effect of uncrosslinked and crosslinked hyaluronic acid combined with other artificial tear components in patients with dry eye caused by moderate meibomian gland dysfunction.Method: Prospective, single-blind, contralateral eye study. Fifty eyes were analyzed (25 patients). Eye selection for each tear type was random, and the eye drop formulations Aquoral Forte® (artificial tear A) and Aquoral Lipo® (artificial tear B) were used. The determined dosing schedule was three times a day for six weeks, and the study participants underwent a clinical examination before and 45 days after lubricant treatment. The Schirmer test, tear breakup time (TBUT) test, and Ocular Surface Disease Index (OSDI) questionnaire were applied before and after instillation period with both types of artificial tears. Results: On the Schirmer test, a significant improvement was obtained with both tear A (p < 0.01) and tear B (p < 0.01). On the TBUT test, a significant improvement was obtained with tear A (p < 0.01) and tear B (p < 0.01). The OSDI score significantly decreased after instillation period with both artificial tear types (p < 0.01). Conclusion: Uncrosslinked hyaluronic acid combined with other components, such as tamarind seed polysaccharide, and crosslinked hyaluronic acid combined with liposomes and crocin are effective for management symptoms of dry eye disease.

show abstract

“…CoQ10 ist eine sehr wirksame Redoxkomponente der Elektronentransportkette in extramitochondrialen Membranen, in denen es antioxidativ und membranstabilisierend wirkt [28]. Es gibt Hinweise darauf, dass CoQ10 möglicherweise eine sinnvolle therapeutische Option für Augenerkrankungen wie das Glaukom [29,30], das "Trockene Auge" [31,32] Literatur…”

Section: Coenzym Q10unclassified

Mitochondriale Dysfunktion und Bedeutung von Coenzym Q10 beim Glaukom

Erb

Konieczka

2018

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

Mitochondrial function is closely linked to numerous aspects of eye health. Imbalance between the creation of energy and the development of reactive oxygen species (ROS) seems to be the cause of the development of mitochondrial dysfunctions. As a result of this energy deficit, the level of oxidative stress in the eye tissues increases, leading to numerous ophthalmic impairments. It is important to distinguish between primary mitochondrial eye diseases and secondary mitochondrial changes. Primary mitochondrial eye diseases, for example Leber's hereditary optic atrophy (LHON), retinitis pigmentosa and chronic progressive external ophthalmoplegia are caused by direct damage to mitochondrial function induced by defective genes, either located on mitochondrial DNA (mtDNA) or the DNA of the nucleus (nDNA). In contrast, secondary mitochondrial dysfunctions are caused by environmental factors. In recent years, there has been growing evidence that mitochondrial dysfunctions play an important role in many common eye diseases, such as glaucoma, dry eye, diabetic retinopathy, cataract and age-related macular degeneration (AMD). This article summarises current knowledge of mitochondrial dysfunctions and the role of coenzyme Q10 (CoQ10) as a possible treatment option - with a special focus on glaucoma.

show abstract

Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye

Abstract: The XLHA + CoQ10 treatment showed greater effectiveness in DED compared to HA alone, probably due to the longer permanency on ocular surface and the antioxidant activity of CoQ10. Therefore, XLHA + CoQ10 eyedrops could represent a new possibility in dry eye treatment.

Cited by 34 publications

References 45 publications

Cross-Linked Hyaluronic Acid as Tear Film Substitute

Cross-Linked Hyaluronic Acid as Tear Film Substitute

Crosslinked hyaluronic acid with liposomes and crocin for management symptoms of dry eye disease caused by moderate meibomian gland dysfunction

Mitochondriale Dysfunktion und Bedeutung von Coenzym Q10 beim Glaukom

Contact Info

Product

Resources

About